Clinical study on growth impairment induced by oral glucocorticoids based on FGF23/Klotho homeostasis observations

TANG Shuai; YANG Yang; LI Xiang; BIE Bing-Yang; ZHANG Jian

doi:10.7499/j.issn.1008-8830.2309160

PDF(786 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (3) : 269-274. DOI: 10.7499/j.issn.1008-8830.2309160

CLINICAL RESEARCH

Clinical study on growth impairment induced by oral glucocorticoids based on FGF23/Klotho homeostasis observations

TANG Shuai, YANG Yang, LI Xiang, BIE Bing-Yang, ZHANG Jian

Author information +

History +

Abstract

Objective To observe the correlation between growth impairment induced by long-term oral glucocorticoids (GC) therapy and the ratio of FGF23/Klotho in children with primary nephrotic syndrome (PNS). Methods A prospective study was conducted on 56 children with GC-sensitive PNS who had discontinued GC therapy for more than 3 months and revisited the Department of Pediatrics of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine between June 2022 and December 2022. After monitoring qualitative and quantitative urine protein levels upon admission, the children with proteinuria relapse were treated with GC (GC group; n=29), while those without relapse did not receive GC treatment (non-GC group; n=27). In addition, 29 healthy children aged 3 to prepuberty were selected as the control group. Height, bone age, growth rate, and the FGF23/Klotho ratio were compared among the groups. The correlations of the FGF23/Klotho ratio with height, bone age, and growth rate were analyzed. Results The FGF23/Klotho ratio in the GC group was significantly higher than that in the non-GC group after 1 month of GC therapy (P<0.05), and the height and bone age growth rates within 6 months were lower than those in the non-GC group (P<0.05). Correlation analysis showed significant negative correlations between the FGF23/Klotho ratio after 1 month of treatment and the growth rates of height and bone age within 6 months in children with PNS (r=-0.356 and -0.436, respectively; P<0.05). Conclusions The disturbance in FGF23/Klotho homeostasis is one of the mechanisms underlying the growth impairment caused by long-term oral GC therapy.

Key words

Primary nephrotic syndrome / Glucocorticosteroid / Growth impairment / FGF23 / Klotho / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

TANG Shuai, YANG Yang, LI Xiang, BIE Bing-Yang, ZHANG Jian. Clinical study on growth impairment induced by oral glucocorticoids based on FGF23/Klotho homeostasis observations[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(3): 269-274 https://doi.org/10.7499/j.issn.1008-8830.2309160

References

1 Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome[J]. Pediatr Nephrol, 2023, 38(3): 877-919. PMID: 36269406. PMCID: PMC9589698. DOI: 10.1007/s00467-022-05739-3.
2 Ma J, Siminoski K, Alos N, et al. Impact of vertebral fractures and glucocorticoid exposure on height deficits in children during treatment of leukemia[J]. J Clin Endocrinol Metab, 2019, 104(2): 213-222. PMID: 30247635. PMCID: PMC6291659. DOI: 10.1210/jc.2018-01083.
3 Delucchi á, Toro L, Alzamora R, et al. Glucocorticoids decrease longitudinal bone growth in pediatric kidney transplant recipients by stimulating the FGF23/FGFR3 signaling pathway[J]. J Bone Miner Res, 2019, 34(10): 1851-1861. PMID: 31099911. DOI: 10.1002/jbmr.3761.
4 Feger M, Ewendt F, Strotmann J, et al. Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23)[J]. J Mol Med (Berl), 2021, 99(5): 699-711. PMID: 33517471. PMCID: PMC8055636. DOI: 10.1007/s00109-021-02036-8.
5 Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways[J]. Physiol Rev, 2012, 92(1): 131-155. PMID: 22298654. PMCID: PMC3306265. DOI: 10.1152/physrev.00002.2011.
6 Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho[J]. J Biol Chem, 2006, 281(10): 6120-6123. PMID: 16436388. PMCID: PMC2637204. DOI: 10.1074/jbc.C500457200.
7 Sp?th SS, Andrade AC, Chau M, et al. Local regulation of growth plate cartilage[J]. Endocr Dev, 2011, 21: 12-22. PMID: 21865750. DOI: 10.1159/000328084.
8 Xie Y, Zhou S, Chen H, et al. Recent research on the growth plate: advances in fibroblast growth factor signaling in growth plate development and disorders[J]. J Mol Endocrinol, 2014, 53(1): T11-T34. PMID: 25114206. DOI: 10.1530/JME-14-0012.
9 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南（2016）[J]. 中华儿科杂志, 2017, 55(10): 729-734. PMID: 29050108. DOI: 10.3760/cma.j.issn.0578-1310.2017.10.003.
10 李辉, 季成叶, 宗心南, 等. 中国0~18岁儿童、青少年身高、体重的标准化生长曲线[J]. 中华儿科杂志, 2009, 47(7): 487-492. PMID: 19951507. DOI: 10.3760/cma.j.issn.0578-1310.2009.07.003.
11 张绍岩, 刘丽娟, 吴真列, 等. 中国人手腕骨发育标准：中华05 I.TW3-CRUS、TW3-C腕骨和RUS-CHN方法[J]. 中国运动医学杂志, 2006, 25(5): 509-516. DOI: 10.3969/j.issn.1000-6710.2006.05.001.
12 Tang Y, Hou L, Sun T, et al. Improved equations to estimate GFR in Chinese children with chronic kidney disease[J]. Pediatr Nephrol, 2023, 38(1): 237-247. PMID: 35467153. DOI: 10.1007/s00467-022-05552-y.
13 Raimann A, Ertl DA, Helmreich M, et al. Fibroblast growth factor 23 and Klotho are present in the growth plate[J]. Connect Tissue Res, 2013, 54(2): 108-117. PMID: 23206185. DOI: 10.3109/03008207.2012.753879.
14 Su N, Jin M, Chen L. Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models[J]. Bone Res, 2014, 2: 14003. PMID: 26273516. PMCID: PMC4472122. DOI: 10.1038/boneres.2014.3.
15 Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling[J]. Endocr Relat Cancer, 2000, 7(3): 165-197. PMID: 11021964. DOI: 10.1677/erc.0.0070165.
16 Stanczyk M, Chrul S, Wyka K, et al. Serum intact fibroblast growth factor 23 in healthy paediatric population[J]. Open Med (Wars), 2021, 16(1): 1022-1027. PMID: 34258392. PMCID: PMC8262519. DOI: 10.1515/med-2021-0288.
17 崔岭, 韦洪艳, 张慧儒, 等. 慢性肾衰患者血清FGF-23、Klotho蛋白水平与疾病严重程度的关系[J]. 河北医药, 2023, 45(12): 1828-1831. DOI: 10.3969/j.issn.1002-7386.2023.12.015.
18 Jennette JC, Olson JL, Silva FG, et al. Heptinstall's Pathology of the Kidney[M]. 7th ed. Amsterdam: Wolters Kluwer Health, 2014: 125-154.